Co-expression of B7–1 with Interleukin-12 Enhances Vaccine-induced Antitumour Immunity in Experimental Myeloma

References

• Hallek, M., Bergsagel, P. L. and Anderson, K. C. (1998). Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3–21.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G. and Berger, L. C. (1998). Growth control mechanisms in multiple myeloma. Leuk. Lymphoma, 29, 465–475.
   PubMed Web of Science ®Google Scholar
• Alexanian, R. and Dimopoulos, M. (1994). The treatment of multiple myeloma. New Eng. J. Med., 330, 484–489.
   PubMed Web of Science ®Google Scholar
• Harousseau, J. L. and Attal, M. (1997). The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semi. Hematol., 34, 61–66.
   PubMed Web of Science ®Google Scholar
• Vile, R. G. and Russell, S. J. (1994). Gene transfer technologies for the gene therapy of cancer. Gene Ther., 1, 88–98.
   PubMed Web of Science ®Google Scholar
• Nielsen, L. L. and Maneval, D. C. (1998). p53 tumour suppressor gene therapy for cancer. Cancer Gene Ther., 5, 52–63.
   PubMed Web of Science ®Google Scholar
• Freeman, S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N. and Marrogi, A. J. (1996). In situ use of suicide genes for cancer therapy. Semi. Oncol., 23, 31–45.
   PubMed Web of Science ®Google Scholar
• Pardoll, D. M. (1998). Cancer vaccines. Nat. Med., 4 (5 Suppl), 525–531.
   PubMed Web of Science ®Google Scholar
• Guillaume, T., Rubinstein, D. B. and Symann, M. (1998). Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood, 92, 1471–1490.
   PubMed Web of Science ®Google Scholar
• Linsley, P. S. and Ledbetter, J. A. (1993). The role of the CD28 receptor during T cell responses to antigen. Ann. Rev. Immunol., 11, 191–212.
   PubMed Web of Science ®Google Scholar
• Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J. and Nadler, L. M. (1994). Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84, 3261–3282.
   PubMed Web of Science ®Google Scholar
• Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P. and Linsley, P. S. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71, 1093–1102.
   PubMed Web of Science ®Google Scholar
• Townsend, S. E. and Allison, J. P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259, 368–370.
   PubMed Web of Science ®Google Scholar
• Baskar, S., Ostrand, R. S., Nabavi, N., Nadler, L. M., Freeman, G. J. and Glimcher, L. H. (1993). Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA, 90, 5687–5690.
   PubMed Web of Science ®Google Scholar
• Wendtner, C.-M., Nolte, A., Mangold, E., Buhmann, R., Maass, G., Chiorini, J. A., Winnacker, E.-L., Emmerich, B., Kotin, R. M. and Hallek, M. (1997). Gene transfer of costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther., 4, 726–735.
   PubMed Web of Science ®Google Scholar
• Huang, A. Y., Bruce, A. T., Pardoll, D. M. and Levitsky, H. I. (1996). Does B7–1 expression confer antigen-presenting capacity to tumors in vivo? J. Exp. Med., 183, 769–776.
   PubMed Web of Science ®Google Scholar
• Cayeux, S., Richter, G., Noffz, G., Dorken, B. and Blankenstein, T. (1997). Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol., 158, 2834–2841.
   PubMed Web of Science ®Google Scholar
• Geldhof, A. B., Raes, G., Bakkus, M., Devos, S., Thielemans, K. and DeBaetselier, P. (1995). Expression of B7–1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res., 55, 2730–2733.
   PubMed Web of Science ®Google Scholar
• Wu, T.-C., Huang, A. Y. C., Jaffee, E., Levitsky, H. I. and Pardoll, D. M. (1995). A reassessment of the role of B7–1 expression in tumor rejection. J. Exp. Med., 182, 1415–1421.
   PubMed Web of Science ®Google Scholar
• Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I. and Hellstrom, K. E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med., 179, 523–532.
   PubMed Web of Science ®Google Scholar
• Ramarathinam, L., Castle, M., Wu, Y. and Liu, Y. (1994). T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med., 179, 1205–1214.
   PubMed Web of Science ®Google Scholar
• Pardoll, D. M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol., 13, 399–415.
   PubMed Web of Science ®Google Scholar
• Trinchieri, G. (1995). Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann. Rev. Immunol, 13, 251–276.
   PubMed Web of Science ®Google Scholar
• Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F. and Gately, M. K. (1993). Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178, 1223–1230.
   PubMed Web of Science ®Google Scholar
• Tahara, H. and Lotze, M. T. (1995). Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther., 2, 96–106.
   PubMed Web of Science ®Google Scholar
• Murphy, E. E., Terres, G., Macatonia, S. E., Hsieh, C. S., Mattson, J., Lanier, L., Wysocka, M., Trinchieri, G., Murphy, K. and O'Garra, A. (1994). B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med., 180, 223–231.
   PubMed Web of Science ®Google Scholar
• Kubin, M., Kamoun, M. and Trinchieri, G. (1994). Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med., 180, 211–222.
   PubMed Web of Science ®Google Scholar
• Gajewski, T. F., Renauld, J.-C., Van Pel, A. and Boon, T. (1995). Costimulation with B7–1, IL-6, and IL-12 is sufficient for primary generation of murine cytolytic T lymphocytes in vitro. J. Immunol., 154, 5637–5648.
   PubMed Web of Science ®Google Scholar
• Geldhof, A. B., Moser, M., Lespagnard, L., Thielemans, K. and De Baetselier, P. (1998). Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood, 91, 196–206.
   PubMed Web of Science ®Google Scholar
• Zitvogel, L., Robbins, P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C. G., Tahara, H., Schreiber, R. D. and Lotze, M. T. (1996). Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol., 26, 1335–1341.
   PubMed Web of Science ®Google Scholar
• Pützer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J. and Graham, F. L. (1997). Interleukin 12 and B7–1 costimulatory molecule expressed by an adeno-virus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA, 94, 10889–10894.
   PubMed Web of Science ®Google Scholar
• Pizzoferrato, E., Chu, N. R., Hawley, T. S., Lieu, F. H. L., Barber, B. H., Hawley, R. G., Watts, T. H. and Berinstein, N. L. (1997). Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7–1 and interleukin-12. Hum. Gene Ther., 8, 2217–2228.
   PubMed Web of Science ®Google Scholar
• Chong, H., Todryk, S., Hutchinson, G., Hart, I. R. and Vile, R. G. (1998). Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther., 5, 223–232.
   PubMed Web of Science ®Google Scholar
• Hawley, T. S., Lach, B., Burns, B. F., May, L. T., Sehgal, P. B. and Hawley, R. G. (1991). Expression of retro-virally transduced IL-1α in IL-6-dependent B cells: A murine model of aggressive multiple myeloma. Growth Factors, 5, 327–338.
   PubMedGoogle Scholar
• Hawley, R. G., Wang, M.-H., Fong, A. Z. C. and Hawley, T. S. (1993). Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas. Clin. Exp. Metastasis, 11, 213–226.
   PubMed Web of Science ®Google Scholar
• Okada, T. and Hawley, R. G. (1995). Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int. J. Cancer, 63, 823–830.
   PubMed Web of Science ®Google Scholar
• Schwarze, M. M. K. and Hawley, R. G. (1995). Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated up-regulation of bcl-xL. Cancer Res., 55, 2262–2265.
   PubMed Web of Science ®Google Scholar
• Klein, B., Zhang, X.-G., Lu, Z.-Y. and Bataille, R. (1995). Interleukin-6 in human multiple myeloma. Blood, 85, 863–872.
   PubMed Web of Science ®Google Scholar
• Zhang, X.-G., Gaillard, J. P., Robillard, N., Lu, Z.-Y., Gu, Z.-J., Jourdan, M., Boiron, J. M., Bataille, R. and Klein, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in multiple myeloma. Blood, 83, 3654–3663.
   PubMed Web of Science ®Google Scholar
• Prince, H. M., Dessureault, S., Gallinger, S., Krajden, M., Sutherland, D. R., Addison, C., Zhang, Y., Graham, F. L. and Stewart, A. K. (1998). Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp. Hematol., 26, 27–36.
   PubMed Web of Science ®Google Scholar
• Harris, J. F., Hawley, R. G., Hawley, T. S. and Crawford-Sharpe, G. (1992). Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6, J. Immunol. Methods, 148, 199–207.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G., Lieu, F. H. L., Fong, A. Z. C., Goldman, S. J., Leonard, J. P. and Hawley, T. S. (1996). Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann. N. Y. Acad. Sci., 795, 341–345.
   PubMed Web of Science ®Google Scholar
• Lieu, F. H. L., Hawley, T. S., Fong, A. Z. C. and Hawley, R. G. (1997). Transmissibility of MSCV-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy. Cancer Gene Ther., 4, 167–175.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G., Lieu, F. H. L., Fong, A. Z. C. and Hawley, T. S. (1994). Versatile retroviral vectors for potential use in gene therapy. Gene Ther., 1, 136–138.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G. (1994). Hematopathology of interleukin-6-type cytokines. Stem Cells, 12 (suppl 1), 155–171.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G., Fong, A. Z. C., Burns, B. F. and Hawley, T. S. (1992). Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J. Exp. Med., 176, 1149–1163.
   PubMed Web of Science ®Google Scholar
• Hawley, T. S., Sabourin, L. A. and Hawley, R. G. (1989). Comparative analysis of retroviral vector expression in mouse embryonal carcinoma cells. Plasmid, 22, 120–131.
   PubMed Web of Science ®Google Scholar
• Hawley, R. G., Fong, A. Z. C., Lu, M. and Hawley, T. S. (1994). The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene, 9, 1–12.
   PubMed Web of Science ®Google Scholar
• Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T. and Blankenstein, T. (1993). Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res., 53, 714–716.
   PubMed Web of Science ®Google Scholar
• Cayeux, S., Richter, G., Becker, C., Beck, C., Aicher, A., Pezzutto, A., Dorken, B. and Blankenstein, T. (1997). Lack of correlation between rejection of tumour cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Eur. J. Immunol., 27, 1657–1662.
   PubMed Web of Science ®Google Scholar
• Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J. and Folkman, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst., 87, 581–586.
   PubMed Web of Science ®Google Scholar
• Kerbel, R. S. and Hawley, R. G. (1995). Interleukin 12: newest member of the antiangiogenesis club. J. Natl. Cancer Inst., 87, 557–559.
   PubMed Web of Science ®Google Scholar
• Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L. and Dalla-Favera, R. (1989). RAS oncogene mutation in multiple myeloma. J. Exp. Med., 170, 1715–1725.
   PubMed Web of Science ®Google Scholar
• Peace, D. J., Smith, J. W., Chen, W., You, S.-G., Cosand, W. L., Blake, J. and Cheever, M. A. (1994). Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J. Exp. Med., 179, 473–479.
   PubMed Web of Science ®Google Scholar
• Kwak, L. W., Taub, D. D., Duffery, L., Bensinger, W. I., Bryant, E. M., Reynolds, C. W. and Longo, D. L. (1995). Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet, 345, 1016–1020.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Vesole, D. H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996). Graft-versus-myeloma effect: proof of principle. Blood, 87, 1196–1198.
   PubMed Web of Science ®Google Scholar
• Stewart, A. K., Meharchand, J., Dubé, I. D., Graham, F. L., Gauldie, J. and Hawley, R. G. (1997). A phase I study of autologous gene modified plasma cell vaccination following peripheral blood stem cell transplantation for the control of minimal residual myeloma, Control No. 049780. Ottawa: Therapeutic Products Directorate, Health Protection Branch, Health Canada.
   Google Scholar
• Stewart, A. K., Schimmer, A. D., Bailey, D. J., Dubé, I. D., Cappe, D., Moen, R. C., Gauldie, J. and Graham, F. L. (1998). In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma. Blood, 91, 1095–1097.
   PubMed Web of Science ®Google Scholar